Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024 ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10. “We are looking forward to sharing data related to our LRG-5 targeted CAR-T program in three poster presentations at the upcoming AACR annual meeting. One of the posters will highlight the GMP manufacturing and testing findings for our lead LGR5-targeted CAR-T cell therapy candidate CNA3103, that is currently being evaluated in a Phase 1/2 clinical trial for the treatment of adult patients with metastatic colorectal cancer,” stated Deborah Rathjen, PhD, Carina’s Chief Executive Officer. “Our research team will also be presenting preclinical data that demonstrate the potential to develop our LGR5-targeting CAR-T cells as a novel immunotherapy for ovarian cancer and that expand the preclinical body of evidence across a diverse range of cancer families, including ovarian, brain, liver, and stomach, where LGR5-targeting CAR-T cells may be harnessed.” Poster Presentation Details
Title: Preclinical in vivo characterization underpinning LGR5-targeting CAR-T cells as a cancer immunotherapy Lead Author: Jade Foeng, PhD, Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, The University of Adelaide, South Australia Session Category: Immunology
Session Date and Time: Sunday, April 7, 2024 1:30 pm PT – 5:00 pm PT
Location: Poster Section 2
Published Abstract Number: 56
Session Category: Clinical Research
Session Title: Adoptive Cell Therapy 2
Session Date and Time: Tuesday, April 9, 2024 1:30 pm PT – 5:00 pm PT
Location: Poster Section 40
Published Abstract Number: 6320
Lead Author: Veronika Bandara, PhD, Molecular Immunology Laboratory, Robinson Research Institute, The University of Adelaide, South Australia Session Category: Clinical Research
Session Title: Adoptive Cell Therapy 2
Session Date and Time: Tuesday, April 9, 2024 1:30 pm PT – 5:00 pm PT
Location: Poster Section 40
Published Abstract Number: 6311
Carina also has a fully integrated, proprietary manufacturing process that has reduced manufacturing time and improved CAR-T cell quality, with the potential to deliver robust “serial-killing” CAR-T cells to patients.
Carina’s preclinical studies of CNA3103 have shown promising results with complete tumor regression and no tumor recurrence following a single administration. CNA3103 has also demonstrated impressive tumor access and prolonged survival enabling the rejection of new tumors. For more information please contact:
stephanie.carrington@westwicke.com